Checking the Hscore for diagnosing hemophagocytosis in intensive care patients
Looks back at how well the Hscore works in intensive care patients.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- Strasbourg, FranceSee the site
- Trial code
- Registry title
- Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 29 Aug 2025
- Planned end
- 29 Aug 2026
- Type of study
- Observational
- Record updated
- 15 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults admitted to intensive care at Hautepierre Hospital, Strasbourg, between January 1, 2014, and December 31, 2024, with blood signs of HLH. HLH is a severe overreaction of the immune system. The study looks back at existing records.
- Age
- 18 years and older
- Sex
- All
- Disease stage
- Patients treated in the intensive care unit with at least 3 blood signs of HLH (lymphohistiocytic hemophagocytosis).
- Biomarker or test result
- Ferritin > 2000 ng/mL; triglycerides > 1.5 g/L; at least one low blood count: leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, or hemoglobin ≤ 9.2 g/dL.
Main reasons for not taking part
- People who refuse to take part in the study cannot join.
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Adult patient (≥18 years old)
- Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024
- At least 3 biological signs of HLH:; ferritin > 2000 ng/mL; triglycerides > 1.5 g/L; at least one cytopenia (leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, hemoglobin ≤ 9.2 g/dL)
Who cannot take part
- Refusal to participate in the study
Where in France
- Médecine intensive - Réanimation - CHU de Strasbourg - FranceStrasbourg, FranceContact: Antonin HUGEROT, MDTaking people
About the trial
What the trial wants to find out
Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings.
Read full original descriptionShow less
In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction.
The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care: Relevance of the Hscore and Search for the Best Diagnostic Markers
- Plain-language title
- Checking the Hscore for diagnosing hemophagocytosis in intensive care patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 15 January 2026